Business Scoop » AUT and Helius partner on medicinal cannabis productsPosted by On


Press Release – Auckland University of Technology

Auckland University of Technology (AUT) and Helius Therapeutics have partnered on the research and development of advanced medicinal cannabis products.
Auckland University of Technology (AUT) and Helius Therapeutics have partnered on the research and development of advanced medicinal cannabis products.

Auckland-based Helius, which focuses on phytocannabinoid research, has taken on three AUT PhD students to work on the next-generation of cannabis therapeutics.

Following the introduction of the medicinal cannabis scheme in April last year, New Zealand’s fledgling medicinal cannabis industry has been focused on local manufacture of medicines, which to date, are only available from overseas.

New Zealand-made products are expected to come to market towards the end of this year and will give New Zealand patients a welcome alternative to overseas and expensive products currently available.

Recently, Helius became New Zealand’s first medicinal cannabis business to gain a GMP (good manufacturing practice) Licence to Manufacture Medicines from the Ministry of Health.

Looking to the future, it is setting up an R&D pipeline for advanced products based on research being done in collaboration with AUT.

“Our vision is to develop novel and efficacious medicines. However, to successfully compete on the world stage, we need to be a leader in the R&D space, particularly in medical innovation. Our work with AUT will lift our…

Original Author Link click here to read complete story..

Press Release – Auckland University of Technology

Auckland University of Technology (AUT) and Helius Therapeutics have partnered on the research and development of advanced medicinal cannabis products.
Auckland University of Technology (AUT) and Helius Therapeutics have partnered on the research and development of advanced medicinal cannabis products.

Auckland-based Helius, which focuses on phytocannabinoid research, has taken on three AUT PhD students to work on the next-generation of cannabis therapeutics.

Following the introduction of the medicinal cannabis scheme in April last year, New Zealand’s fledgling medicinal cannabis industry has been focused on local manufacture of medicines, which to date, are only available from overseas.

New Zealand-made products are expected to come to market towards the end of this year and will give New Zealand patients a welcome alternative to overseas and expensive products currently available.

Recently, Helius became New Zealand’s first medicinal cannabis business to gain a GMP (good manufacturing practice) Licence to Manufacture Medicines from the Ministry of Health.

Looking to the future, it is setting up an R&D pipeline for advanced products based on research being done in collaboration with AUT.

“Our vision is to develop novel and efficacious medicines. However, to successfully compete on the world stage, we need to be a leader in the R&D space, particularly in medical innovation. Our work with AUT will lift our…



Source link

News

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.